EUCTR2006-005568-24-DEActive, not recruitingNot Applicable
Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) in verschiedenen VerdünnungenEvaluation of the Efficacy and Safety of Botulinumtoxin (Xeomin®) in different dilutions
Dermatologikum Hamburg0 sitesStarted: December 4, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Male or female subjects between 18 and 75 years of age with moderate to severe glabellar frown lines (severity score = 2 as assessed by the investigator according to Facial Wrinkle Scale)
- •2. Stable medical condition
- •3. Subject willing and able to realize the entire course of trial and to comply with trial instructions
- •5. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Previous treatment with Botulinum toxin in the glabellar area within the last 6 months prior to study start
- •2. Any previous insertion of permanent filler material in the glabellar area
- •3. Previous treatments with facial cosmetic procedures (e.g. dermal filling, chemical peeling, photo rejuvenation) in the glabellar area within the last 9 months prior to study start
- •4. Planned treatment with Botulinum toxin in any additional body region during the study period
- •5. Planned additional treatment with any facial cosmetic procedure (e.g. dermal filling, chemical peeling, photo rejuvenation) in the glabellar area during the study participation
- •6. Any surgical pretreatment or scars in the glabellar area
- •7. Any infection in the area of the injection sites
- •8. Known allergy or sensitivity to the trial medication or its components, or any medical condition that may expose the subject to an increased risk by exposure to Xeomin including diagnosed myasthenia gravis, Lambert-Eaton Syndrome, amyotrophic lateral sclerosis or any other disorder that might interfere with neuromuscular function
- •9. History of facial nerve palsy
- •10. Bleeding disorders or regular intake of drugs with anticoagulative effect within the last 10 days prior to study start
- •11. Concurrent use of aminoglycosides (antibiotics) or other agents that might interfere with neuromuscular function or action of Botulinum toxin
Investigators
Similar Trials
Completed
Phase 4
A clinical trial to study the effect of a Under eye Skin cream containing Biophytex LS 8740 and Proteasyl TP LS 8657 in patients with under eye dark circles.CTRI/2010/091/001346Glenmark Pharmaceutical limited500
Completed
Phase 4
A clinical trial to assess the efficacy, safety and tolerability of tigecycline in adult hospitalized patients with community acquired pneumonia (CAP).CTRI/2010/091/001439Glenmark Pharmaceuticals Limited120
Not yet recruiting
Phase 3
To evaluate the effectiveness and acceptability of the fluoridated toothpaste to prevent plaque and gum diseases in children in the age group of 6 to 12 yearsCTRI/2024/02/062692Avoden pvt ltd
Active, not recruiting
Not Applicable
Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCEMULTIPLE SCLEROSISEUCTR2005-006071-12-ITAZIENDA OSPEDALIERA SAN CAMILLO FORLANINI276
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150